Intangible Assets

ERNA’s latest provided metrics show negative ROIC and ROCE, which indicates the company is not converting any presumed IP or regulatory know-how into durable economic returns versus peers.

No filing-based evidence was provided for patents, proprietary formulations, or exclusive licenses, so there is no demonstrated intangible asset base that would support pricing power or retention.

With no visible margin history or 5-year profitability averages in the supplied data, there is no peer-relative proof that any brand or scientific asset is sustaining superior economics over time.

In a peer set, companies with defensible patents, approved indications, or exclusive distribution rights would score materially higher because those assets directly protect margins and customer stickiness, while ERNA’s current evidence does not.

Switching Costs

The provided metrics do not show positive returns or operating leverage, which suggests customers are not locked in by high switching costs that preserve economics versus peers.

No filing evidence was provided for long-duration contracts, embedded workflows, or regulatory dependence that would make replacement costly for customers.

Negative ROIC and ROCE are inconsistent with a business that can retain customers through switching frictions strong enough to support durable pricing power.

Compared with peers that benefit from recurring prescriptions, protocol integration, or reimbursement-linked inertia, ERNA currently shows no documented switching-cost advantage.

Network Effects

The supplied data contains no evidence of user-to-user, provider-to-provider, or data-network flywheels that would compound value over time.

Negative profitability metrics indicate any scale in usage is not yet translating into a self-reinforcing ecosystem advantage versus peers.

No filings or third-party sources were provided showing platform adoption, ecosystem lock-in, or network-dependent demand that would raise retention.

Relative to peers with clear network effects in diagnostics, marketplaces, or software-enabled care coordination, ERNA shows no demonstrated network moat.

Cost Advantage

Negative ROIC and ROCE imply ERNA is not operating with a cost structure that converts into superior unit economics versus peers.

The provided data does not show asset efficiency or margin durability, so there is no evidence of a structural cost edge from manufacturing, scale procurement, or process superiority.

A zero asset-turnover reading in the supplied metrics further weakens the case that the company has a repeatable operating advantage over competitors.

Peers with lower COGS, higher throughput, or advantaged scale purchasing would score higher because those traits directly protect margins, while ERNA’s current evidence does not.

Efficient Scale

No filing evidence was provided that ERNA operates in a naturally limited market where one or two firms can profitably serve demand and deter entry.

The negative return profile suggests the company has not yet reached a scale position that allows it to earn excess returns from market structure versus peers.

There is no supplied evidence of regulatory barriers, capacity constraints, or exclusive access that would make the market efficiently served by a small number of incumbents.

Compared with peers in regulated or infrastructure-like niches, ERNA does not currently show the kind of scarce-scale advantage that would support a durable moat.

Overall Score

Based on the supplied metrics and absence of filing-based evidence for patents, exclusivity, lock-in, or ecosystem control, ERNA shows no demonstrated durable moat versus peers and currently appears structurally weak.